Details of the Drug
General Information of Drug (ID: DMTNZKU)
Drug Name |
6-MORPHOLIN-4-YL-9H-PURINE
|
|||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
2846-96-0; 6-Morpholinopurine; 6-(morpholin-4-yl)-9H-purine; 6-Morpholin-4-Yl-9h-Purine; 4-(1H-Purin-6-yl)morpholine; 4-(9h-purin-6-yl)morpholine; 4-(7H-purin-6-yl)morpholine; SMR000017638; MLS000080575; 2wmu; EINECS 220-645-3; 4-purin-6-ylmorpholine; 6-morpholino-9H-purine; 6-Morpholino-1H-purine; AC1Q4X9J; AC1Q1I5S; Oprea1_261650; Oprea1_519977; MLS000104086; SCHEMBL336612; CHEMBL271138; AC1L2Q64; BDBM33210; CTK4G1553; 9H-Purine,6-(4-morpholinyl)-; DTXSID80182656; MEOMXKNIFWDDGZ-UHFFFAOYSA-N; MolPort-002-610-718; HMS2298A04
|
|||||||||||||||||||
Indication |
|
|||||||||||||||||||
Drug Type |
Small molecular drug
|
|||||||||||||||||||
Structure |
![]() |
|||||||||||||||||||
3D MOL | 2D MOL | |||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 205.22 | ||||||||||||||||||
Topological Polar Surface Area (xlogp) | 0.3 | |||||||||||||||||||
Rotatable Bond Count (rotbonds) | 1 | |||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | |||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 5 | |||||||||||||||||||
Chemical Identifiers |
|
|||||||||||||||||||
Cross-matching ID | ||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||
References